Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVIA 113 long-term immune persistence study of EuTCV in Senegalese children
PACTR202605522385822Not yet recruiting
- Sponsor
- EuBiologics
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of Typhoid Vi conjugate vaccine and EuTYPH-C in typhoid fever (3 arms), sponsored by EuBiologics. Primary endpoint: Seroconversion rate of anti-Vi IgG ELISA titers. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Typhoid Vi conjugate vaccineEuTYPH-C
03
Conditions
typhoid fever
Beyond the preview
Go deeper on PACTR202605522385822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605522385822.